Shares of Edwards Lifesciences Corporation (NYSE:EW – Get Free Report) have received an average rating of “Moderate Buy” from the twenty-six ratings firms that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and twenty-three have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $109.88.
A number of research analysts recently issued reports on the company. BTIG Research boosted their price objective on Edwards Lifesciences from $110.00 to $115.00 and gave the company a “buy” rating in a research report on Thursday, November 5th. Weiss Ratings raised Edwards Lifesciences from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, November 9th. Argus raised their target price on Edwards Lifesciences from $105.00 to $115.00 and gave the company a “buy” rating in a research note on Friday, August 21st. JPMorgan Chase & Co. raised their target price on Edwards Lifesciences from $105.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, November 5th. Finally, Barclays boosted their price target on shares of Edwards Lifesciences from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, November 5th.
Check Out Our Latest Stock Report on EW
Insider Activity
In other Edwards Lifesciences news, VP Annette Brüls sold 2,644 shares of the company’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president owned 17,984 shares in the company, valued at approximately $1,618,200.32. This represents a 12.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 48,900 shares of the firm’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $103.05, for a total transaction of $5,039,145.00. Following the completion of the sale, the vice president owned 22,798 shares in the company, valued at $2,349,333.90. The trade was a 68.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 53,945 shares of company stock worth $5,498,306 in the last 90 days. 0.31% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of EW. RMG Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the first quarter valued at about $26,000. Pin Oak Investment Advisors Inc. bought a new position in Edwards Lifesciences in the 2nd quarter valued at about $26,000. GK Wealth Management LLC bought a new position in Edwards Lifesciences in the 3rd quarter valued at about $26,000. TrinityBridge Ltd acquired a new position in shares of Edwards Lifesciences during the second quarter valued at approximately $27,000. Finally, Meeder Asset Management Inc. raised its holdings in Edwards Lifesciences by 175.2% during the first quarter. Meeder Asset Management Inc. now owns 366 shares of the medical research company’s stock worth $29,000 after purchasing an additional 233 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.
Edwards Lifesciences Stock Performance
Shares of NYSE EW opened at $101.87 on Friday. The company has a quick ratio of 3.86, a current ratio of 4.60 and a debt-to-equity ratio of 0.05. The firm’s 50-day moving average price is $92.19 and its two-hundred day moving average price is $86.89. Edwards Lifesciences has a 52-week low of $74.66 and a 52-week high of $108.00. The stock has a market capitalization of $58.57 billion, a P/E ratio of 57.55, a P/E/G ratio of 2.72 and a beta of 0.85.
Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its earnings results on Wednesday, November 4th. The medical research company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.74 by $0.06. The company had revenue of $1.72 billion during the quarter, compared to analyst estimates of $1.68 billion. Edwards Lifesciences had a return on equity of 16.06% and a net margin of 15.30%. The business’s revenue was up 10.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.67 earnings per share. As a group, sell-side analysts forecast that Edwards Lifesciences will post 3.01 earnings per share for the current year.
Edwards Lifesciences Company Profile
Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery. The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.
Featured Stories
- Five stocks we like better than Edwards Lifesciences
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
